drugset / Trial / NCT03554291

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

NCT03554291 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.

Timeline

Start
2019-05-01
Primary completion
2023-07-11
Completion
2023-07-11

Outcome

Missed primary endpoint

paper No significant difference in the primary outcome of 6MWD at 24 weeks was found PMID 39761829 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 20 mg Oral